Nexien BioPharma, Inc.

NXEN

US65343D1000

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 07:55:07 13/05/2024 pm IST			5-day change	1st Jan Change
0.0163 ^USD	-28.04%		0.00%	-37.07%

20/02	Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Nexien BioPharma, Inc. Auditor Raises 'Going Concern' Doubt

September 28, 2022

Nexien BioPharma, Inc. filed its 10-K on Sep 28, 2022 for the period ending Jun 30, 2022. In this report its auditor, M & K CPAS, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Nexien BioPharma, Inc.

Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	20/02	CI
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	15/11	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28/23/28	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	17/23/17	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	08/23/08	CI
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	09/22/09	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	28/22/28	CI
Nexien BioPharma, Inc. Auditor Raises 'Going Concern' Doubt	28/22/28	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	12/22/12	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	08/22/08	CI
Nexien BioPharma, Inc. announced that it has received $0.15 million in funding from Quick Capital, LLC	18/22/18	CI
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	22/21/22	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021	12/21/12	CI
Nexien BioPharma, Inc. Auditor Raises 'Going Concern' Doubt	12/21/12	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2021	05/21/05	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2020	12/21/12	CI
Nexien Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2020	10/20/10	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2020	28/20/28	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2020	14/20/14	CI
Nexien BioPharma, Inc. Announces Management Changes	07/20/07	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2019	12/20/12	CI
Nexien Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2019	12/19/12	CI
Nexien BioPharma, Inc. Announces Resignation of Courtney Clark from Director	22/19/22	CI
Intiva Biopharma Inc. Reports Earnings Results for the Full Year Ended June 30, 2019	30/19/30	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2019	14/19/14	CI

Chart Nexien BioPharma, Inc.

Duration

Period

More charts

Company Profile

Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NEXIEN BIOPHARMA, INC.	-37.07%	15.28L
ELI LILLY AND COMPANY	+29.98%	68TCr
NOVO NORDISK A/S	+30.34%	57TCr
JOHNSON & JOHNSON	-3.52%	36TCr
MERCK & CO., INC.	+18.59%	33TCr
ABBVIE INC.	+4.07%	28TCr
ASTRAZENECA PLC	+16.21%	24TCr
NOVARTIS AG	+9.66%	21TCr
ROCHE HOLDING AG	-6.83%	20TCr
AMGEN INC.	+7.09%	17TCr

Other Pharmaceuticals